1 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford , Oxford, United Kingdom .
Stem Cells Dev. 2013 Dec;22 Suppl 1(Suppl 1):63-72. doi: 10.1089/scd.2013.0403.
Increased global connectivity has catalyzed technological development in almost all industries, in part through the facilitation of novel collaborative structures. Notably, open innovation and crowd-sourcing-of expertise and/or funding-has tremendous potential to increase the efficiency with which biomedical ecosystems interact to deliver safe, efficacious and affordable therapies to patients. Consequently, such practices offer tremendous potential in advancing development of cellular therapies. In this vein, the CASMI Translational Stem Cell Consortium (CTSCC) was formed to unite global thought-leaders, producing academically rigorous and commercially practicable solutions to a range of challenges in pluripotent stem cell translation. Critically, the CTSCC research agenda is defined through continuous consultation with its international funding and research partners. Herein, initial findings for all research focus areas are presented to inform global product development strategies, and to stimulate continued industry interaction around biomanufacturing, strategic partnerships, standards, regulation and intellectual property and clinical adoption.
全球化的互联互通促进了几乎所有行业的技术发展，部分原因是新型合作结构的推动。值得注意的是，开放式创新和专业知识以及/或资金的众包具有巨大的潜力，可以提高生物医学生态系统相互作用的效率，为患者提供安全、有效和负担得起的治疗方法。因此，这些实践在推进细胞疗法的发展方面具有巨大的潜力。有鉴于此，成立了 CASMI 转化干细胞联盟 (CTSCC)，将全球思想领袖团结在一起，针对多能干细胞转化过程中的一系列挑战，提出学术严谨、商业可行的解决方案。至关重要的是，通过与国际资助和研究伙伴的持续协商来确定 CTSCC 的研究议程。在此，报告所有研究重点领域的初步发现，以告知全球产品开发策略，并围绕生物制造、战略伙伴关系、标准、法规和知识产权以及临床应用，激发行业持续互动。
